NASDAQ · ICCM
IceCure Medical financials
$1.59−2.45%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $3.4M | $3.3M | $3.2M | $3.1M | $4.1M |
| Gross profit | $1.2M | $1.5M | $1.3M | $1.4M | $2.2M |
| Gross margin | 36.3% | 44.1% | 40.3% | 46.8% | 53.0% |
| Operating income | -$15.1M | -$15.7M | -$15.6M | -$16.7M | -$9.7M |
| Net income | -$15.1M | -$15.3M | -$14.7M | -$17.0M | -$9.9M |
| Net margin | −445.6% | −465.5% | −453.8% | −550.3% | −239.1% |
| Diluted EPS | $-7.20 | $-9.00 | $-9.60 | $-13.80 | $-10.50 |
| EBITDA | -$14.8M | -$15.4M | -$15.3M | -$16.5M | -$9.6M |
| Operating cash flow | -$14.6M | -$12.6M | -$12.6M | -$14.3M | -$12.6M |
| Free cash flow | -$14.6M | -$12.6M | -$13.0M | -$15.2M | -$13.1M |
| Diluted shares | 2.1M | 1.7M | 1.5M | 1.2M | 1.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $8.9M | $7.6M | $10.5M | $23.7M | $25.6M |
| Short-term investments | $0.00 | $0.00 | $529.0K | $0.00 | $0.00 |
| Total debt | $13.0K | $161.0K | $0.00 | $0.00 | $618.0K |
| Total assets | $13.9M | $12.6M | $16.4M | $30.2M | $32.3M |
| Total liabilities | $4.8M | $5.7M | $4.2M | $4.8M | $5.3M |
| Shareholders' equity | $9.1M | $6.9M | $12.2M | $25.4M | $27.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology